Dr. Uzzo on the Guidelines for the Management of Kidney Cancer

Robert G. Uzzo, MD
Published: Thursday, Sep 28, 2017



Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the guidelines for the treatment and management of patients with kidney cancer.

There is an increasing emphasis on biopsy to determine and risk-stratify patients prior to any plans for excision, ablation, or observation. The use of percutaneous biopsy as a risk-stratifying tool is an important aspect of all the guidelines.

Many physicians believe that biopsy is associated with a risk of tumor spillage, which fortunately is not the case, states Uzzo. Biopsy does not seem to be associated with a higher-risk of tumor dissemination.
 


Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the guidelines for the treatment and management of patients with kidney cancer.

There is an increasing emphasis on biopsy to determine and risk-stratify patients prior to any plans for excision, ablation, or observation. The use of percutaneous biopsy as a risk-stratifying tool is an important aspect of all the guidelines.

Many physicians believe that biopsy is associated with a risk of tumor spillage, which fortunately is not the case, states Uzzo. Biopsy does not seem to be associated with a higher-risk of tumor dissemination.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x